☰

Vincent Potiron - Publications

Affiliations: 
Université de Poitiers. UFR des sciences fondamentales et appliquées 
Tree Info Grants Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Labbé M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, Fradin D. microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer. 19: 63. PMID 32293453 DOI: 10.1186/S12943-020-01186-6  0.346
2020 Briand J, Garnier D, Nadaradjane A, Clément-Colmou K, Potiron V, Supiot S, Bougras-Cartron G, Frenel JS, Heymann D, Vallette FM, Cartron PF. Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics. 12: 397-408. PMID 32267172 DOI: 10.2217/Epi-2019-0193  0.382
2020 Clément-Colmou K, Potiron V, Pietri M, Guillonneau M, Jouglar E, Chiavassa S, Delpon G, Paris F, Supiot S. Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models. Cancers. 12. PMID 31906502 DOI: 10.3390/Cancers12010121  0.375
2019 Potiron V, Clément-Colmou K, Jouglar E, Pietri M, Chiavassa S, Delpon G, Paris F, Supiot S. Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Letters. 457: 1-9. PMID 31078733 DOI: 10.1016/J.Canlet.2019.05.005  0.368
2019 Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 133: 16-19. PMID 30935573 DOI: 10.1016/J.Radonc.2018.12.022  0.304
2013 Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Research. 73: 7111-21. PMID 24121493 DOI: 10.1158/0008-5472.Can-13-1755  0.78
2011 Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Letters. 300: 66-78. PMID 20980099 DOI: 10.1016/J.Canlet.2010.09.007  0.784
2011 Potiron V, Drabkin H, Roche J. SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/44387  0.559
2010 Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adhesion & Migration. 4: 130-45. PMID 20139699 DOI: 10.4161/Cam.4.1.10882  0.783
2010 Roche J, Nasarre P, Potiron V, Nair-Menon J, Gemmill R, Drabkin H. Abstract 4969: Neuropilin-2 is downregulated by Snail during EMT in lung cancer Cancer Research. 70: 4969-4969. DOI: 10.1158/1538-7445.Am10-4969  0.803
2009 Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia (New York, N.Y.). 11: 157-66. PMID 19177200 DOI: 10.1593/Neo.81074  0.801
2009 Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Letters. 273: 1-14. PMID 18625544 DOI: 10.1016/J.Canlet.2008.05.032  0.702
2008 Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? British Journal of Cancer. 99: 1153-60. PMID 18781179 DOI: 10.1038/Sj.Bjc.6604641  0.742
2007 Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research. 67: 8708-15. PMID 17875711 DOI: 10.1158/0008-5472.Can-06-3612  0.756
2007 Loudni L, Roche J, Potiron V, Clarhaut J, Bachmann C, Gesson JP, Tranoy-Opalinski I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 4819-23. PMID 17624773 DOI: 10.1016/J.Bmcl.2007.06.067  0.737
2007 Potiron V, Nasarre P, Roche J, Healy C, Boumsell L. Semaphorin signaling in the immune system. Advances in Experimental Medicine and Biology. 600: 132-44. PMID 17607952 DOI: 10.1007/978-0-387-70956-7_11  0.739
2005 Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochimica Et Biophysica Acta. 1730: 66-76. PMID 16005989 DOI: 10.1016/J.Bbaexp.2005.05.008  0.652
2005 Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (New York, N.Y.). 7: 457-65. PMID 15967098 DOI: 10.1593/Neo.04721  0.79
2005 Potiron V, Roche J. Class 3 semaphorin signaling: the end of a dogma. Science's Stke : Signal Transduction Knowledge Environment. 2005: pe24. PMID 15914725 DOI: 10.1126/Stke.2852005Pe24  0.65
Show low-probability matches.